Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hemolytic anemia is a common clinical disease with diverse pathogenesis. In recent years, the incidence of hemolytic anemia is increasing dramatically. The present clinical treatment of immunosuppressive agents or splenectomy is effective to some extent; however, the accompanied clinical adverse reactions are also significant. Traditional Chinese medicine (TCM) has beneficial therapeutic effect on hemolytic anemia, with the obvious advantages including curative effect, less adverse reactions, and low price. The pathogenesis of hemolytic anemia as well as the pharmacological effects and mechanisms of the compound, single herb, and monomer composition of TCM in the treatment of hemolytic anemia were reviewed, aiming to provide the basis for the clinical treatment of hemolytic anemia and the modern research on the mechanism of TCM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19540/j.cnki.cjcmm.20180611.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Healthcare providers' knowledge on sickle cell disease and its management: A pre- and post-training test evaluation outcome.
PLoS One
September 2025
Department of Internal Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
In resource-limited settings in Africa, which harbour the greatest burden of Sickle Cell Disease (SCD) globally, poor care outcomes are driven in part, by a lack of trained healthcare providers (HCP) and an absence of context-specific treatment guidelines appropriate to the level of healthcare facility. The study aimed to evaluate the impact of a structured training program on HCP's knowledge of SCD in Ghana. This was prospective cross-sectional study involving HCPs from 46 health facilities from 4 out of 16 regions in Ghana.
View Article and Find Full Text PDFParoxysmal Nocturnal Hemoglobinuria (PNH) clones are frequently found in hypoplastic myelodysplastic syndromes (hMDS), though less commonly than in aplastic anemia. In contrast, the coexistence of hemolytic PNH with large clones and classical, hypercellular MDS (non-hMDS) is rare and likely underrecognized in clinical practice. Since 2014, 229 MDS patients have been seen at our department.
View Article and Find Full Text PDFSickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approaches.
Front Pharmacol
August 2025
Department of Pharmacy, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Malaysia.
Sickle cell disease (SCD) is an inherited blood disorder marked by the production of abnormal hemoglobin, leading to the distortion-or sickling-of red blood cells. The SCD arises from a single-point mutation that substitutes glutamic acid with valine at the sixth codon of the β-globin chain in hemoglobin. This substitution promotes deoxyhemoglobin aggregation, elevating red blood cell stiffness, and triggering vaso-occlusive and hemolytic repercussions.
View Article and Find Full Text PDFGlycoproteomics analysis of complement factor H and its complement-regulatory function during -associated hemolytic uremic syndrome.
Front Immunol
September 2025
Department of Pediatric Nephrology, Radboud University Medical Centre, Amalia Children's Hospital, Nijmegen, Netherlands.
Hemolytic uremic syndrome caused by an invasive infection (SP-HUS) is a rare and severe disease that primarily affects children under two years of age. The pathophysiology of SP-HUS remains poorly understood, and treatment is largely supportive. Complement factor H (FH) is a key regulator of the alternative pathway of the complement system.
View Article and Find Full Text PDFAutoimmune Hemolytic Anemia From Tofacitinib Use in a Patient With Ulcerative Colitis.
ACG Case Rep J
October 2024
Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland Medical System, Baltimore, MD.
Tofacitinib is a Janus kinase inhibitor commonly used in the management of rheumatoid arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this medication often with minimal changes in hemoglobin levels. We report the first case of autoimmune hemolytic anemia from tofacitinib use in a patient with inflammatory bowel disease.
View Article and Find Full Text PDF